Valence 标志
热门
登录

添加到自选股

Amneal Pharmaceuticals In...

NasdaqGS: AMRX · 实时价格 · USD
18.42
+0.27 (1.49%)
收盘价： Aug 18, 2026, 11:36 AM

Amneal Pharmaceuticals Inc. (AMRX) Stock Price, Analysis & Data

1.49%
买价n/a
市值6.42B
营收（TTM）3.12B
净利润（TTM）157.36M
贝塔值1.25
每股收益（TTM）0.48
市盈率（TTM）38.38
预期市盈率15.35
市净率（TTM）178.83
市销率（TTM）2.06
Earnings DateMay 4, 2026
卖价n/a
成交量1,563,485
20日均量2,019,419
开盘价18.01
前收盘价18.15
日内区间17.92 - 18.44
52周区间9.20 - 19.26
分析师Strong Buy
目标价21 (14.01%)
分红n/a
除息日n/a

关于 AMRX

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and e...

[阅读更多]
行业 Drug Manufacturers - Specialty & Generic
板块 Healthcare
上市日期 May 7, 2018
员工人数 8,700
交易所 NasdaqGS
股票代码 AMRX
官网 https://www.amneal.com
公司完整简介

财务表现

2025年，Amneal Pharmaceuticals的营收为3.02B，较上一年的2.79B增长8.05%。 净利润为72.06M，下降-161.65%。

财务报表

分析师预测

根据4位分析师的评级，AMRX的平均评级为“Strong Buy”。12个月目标价为21，较最新价格上涨空间14.01%。

股票预测

财报意外

Amneal Pharmaceuticals 已于 Jul 30, 2026 发布季度财报：
  • 营收为 $796.2M 低于预期 $0, ， 9.89% 同比增长.
  • 每股收益为 0.3 超出预期 0.07, ， 20.00% 同比增长.

    • 下次财报发布时间

    Amneal Pharmaceuticals Inc. 计划于以下时间发布财报 May 4, 2026, 收盘后。
    分析师预计营收为 ... 升级
    news image

    刚刚 · StockStory

    3 Profitable Stocks That Fall Short

    While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my...

    news image

    3天前 · Zacks

    Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus

    KOD's Zenkuda advances toward regulatory submission as its pipeline gains momentum. Key clinical data is expected later in 2026.

    news image

    3天前 · Zacks

    CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains

    CorMedix stock rises 15% after Q2 earnings and revenues beat estimates, driven by solid DefenCath utilization and contributions from the Melinta portfolio.

    news image

    4天前 · Zacks

    ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus

    Altimmune posts a narrower Q2 loss. Its $519M in cash supports operations into 2029, while pemvidutide advances across liver and AUD studies.

    news image

    5天前 · Zacks

    BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA

    Belite Bio's tinlarebant wins FDA priority review for Stargardt Disease, with a decision expected in February 2027 after positive phase III data.

    第 1 页，共 2 页